Cholecystokinin Receptor Antagonist Halts Progression of Pancreatic Cancer Precursor Lesions and Fibrosis in Mice
暂无分享,去创建一个
Christopher O. McGovern | J. S. Gutkind | A. Molinolo | G. Matters | Jill P. Smith | T. Cooper | Jiangang Liao | Qing Zhong | Evan L. Gilius | J. Gutkind | J. Gutkind | Jill P. Smith | Timothy K. Cooper
[1] Haojie Huang,et al. Oncogenic K-Ras requires activation for enhanced activity , 2014, Oncogene.
[2] Jill P. Smith,et al. Cholecystokinin and pancreatic cancer: the chicken or the egg? , 2014, American journal of physiology. Gastrointestinal and liver physiology.
[3] T. Brentnall,et al. Screening and surgical outcomes of familial pancreatic cancer. , 2013, The Surgical clinics of North America.
[4] C. Logsdon,et al. Roles for KRAS in pancreatic tumor development and progression. , 2013, Gastroenterology.
[5] A. Saluja,et al. Relevance of animal models of pancreatic cancer and pancreatitis to human disease. , 2013, Gastroenterology.
[6] Li-xi Yang,et al. Current status in chemotherapy for advanced pancreatic adenocarcinoma. , 2013, Anticancer research.
[7] S. Pandol,et al. A starring role for stellate cells in the pancreatic cancer microenvironment. , 2013, Gastroenterology.
[8] J. Antunes-Rodrigues,et al. Cardiovascular and Inflammatory Response to Cholecystokinin During Endotoxemic Shock , 2013, Shock.
[9] A. Grothey,et al. Treatment options for advanced pancreatic cancer: a review , 2012, Expert review of anticancer therapy.
[10] Manuel Hidalgo,et al. Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas , 2012, Clinical Cancer Research.
[11] Derek S. Chan,et al. The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.
[12] Christopher O. McGovern,et al. Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis. , 2012, American journal of physiology. Gastrointestinal and liver physiology.
[13] S. Kulp,et al. A Review of the Existing Grading Schemes and a Proposal for a Modified Grading Scheme for Prostatic Lesions in TRAMP Mice , 2012, Toxicologic pathology.
[14] S. Möller,et al. Identification of quantitative trait loci for murine autoimmune pancreatitis , 2011, Journal of Medical Genetics.
[15] Christopher O. McGovern,et al. Role of endogenous cholecystokinin on growth of human pancreatic cancer. , 2011, International journal of oncology.
[16] H. Dietz,et al. The Haploinsufficient Col3a1 Mouse as a Model for Vascular Ehlers-Danlos Syndrome , 2010, Veterinary pathology.
[17] M. Guilhaus,et al. Pancreatic stellate cells produce acetylcholine and may play a role in pancreatic exocrine secretion , 2010, Proceedings of the National Academy of Sciences.
[18] A. Lohse,et al. CCK1 and CCK2 Receptors Are Expressed on Pancreatic Stellate Cells and Induce Collagen Production , 2010, The Journal of Biological Chemistry.
[19] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[20] Joshua I. Suhonen,et al. Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival. , 2010, Endocrinology.
[21] T. Meyer,et al. A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. , 2010, European journal of cancer.
[22] M. Peyton,et al. Protection Against Chronic Pancreatitis and Pancreatic Fibrosis in Mice Overexpressing Pancreatic Secretory Trypsin Inhibitor , 2010, Pancreas.
[23] Christopher O. McGovern,et al. Growth of Human Pancreatic Cancer Is Inhibited by Down-Regulation of Gastrin Gene Expression , 2009, Pancreas.
[24] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[25] M. Korc,et al. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. , 2009, Biochemical and biophysical research communications.
[26] R. Jensen,et al. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. , 2007, Current opinion in pharmacology.
[27] R. Jensen,et al. Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. , 2007, Current topics in medicinal chemistry.
[28] S. Watson,et al. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy , 2007, Expert opinion on biological therapy.
[29] David A. Tuveson,et al. The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics , 2006, Clinical Cancer Research.
[30] T. Hickish,et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials , 2006, British Journal of Cancer.
[31] N. Shankley,et al. Advanced qRT-PCR Technology Allows Detection of the Cholecystokinin 1 Receptor (CCK1R) Expression in Human Pancreas , 2005, Pancreas.
[32] Di-tian Liu,et al. Long-term effects of proglumide on resection of cardiac adenocarcinoma. , 2005, World Journal of Gastroenterology.
[33] Michael Goggins,et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. , 2005, Cancer research.
[34] J S Wilson,et al. Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells , 2004, Pancreas.
[35] R. DePinho,et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.
[36] L. Miller,et al. Heterodimerization of Type A and B Cholecystokinin Receptors Enhance Signaling and Promote Cell Growth* , 2003, Journal of Biological Chemistry.
[37] E. Petricoin,et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.
[38] R. Herranz. Cholecystokinin antagonists: Pharmacological and therapeutic potential , 2003, Medicinal research reviews.
[39] K. Shiratori,et al. Clinical Evaluation of Oral Administration of a Cholecystokinin-A Receptor Antagonist (Loxiglumide) to Patients with Acute, Painful Attacks of Chronic Pancreatitis: A Multicenter Dose–Response Study in Japan , 2002, Pancreas.
[40] R H Hruban,et al. Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] R. Codoceo,et al. Relationship of Basal and Postprandial Intraduodenal Bile Acid Concentrations and Plasma Cholecystokinin Levels with Abdominal Pain in Patients with Chronic Pancreatitis , 1998, Pancreas.
[42] J. Menani,et al. Cholecystokinin actions in the parabrachial nucleus: effects on thirst and salt appetite. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.
[43] J. P. Smith,et al. Quantitative analysis of gastrin mRNA and peptide in normal and cancerous human pancreas. , 1998, International journal of molecular medicine.
[44] S. Waldman,et al. Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. , 1997, The Journal of clinical investigation.
[45] A. Nishida,et al. (3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)- 1H-1,4-benzodiazepin-3-yl)-N′-(3(methylamino)phenyl)urea (YF476): A Potent and Orally Active Gastrin/CCK-B Antagonist. , 1997 .
[46] A. Nishida,et al. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. , 1997, Journal of medicinal chemistry.
[47] J. P. Smith,et al. Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. , 1996, The American journal of physiology.
[48] J. P. Smith,et al. Cholecystokinin receptors and PANC-1 human pancreatic cancer cells. , 1993, The American journal of physiology.
[49] C. Niederau,et al. Effects of Cholecystokinin Receptor Blockade on Circulating Concentrations of Glucose, Insulin, C‐Peptide, and Pancreatic Polypeptide after Various Meals in Healthy Human Volunteers , 1992, Pancreas.
[50] Jill P. Smith,et al. CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium , 1991, Regulatory Peptides.
[51] Jill P. Smith,et al. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990 , 1990, Digestive Diseases and Sciences.
[52] M. Bock,et al. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. , 1989, Molecular pharmacology.
[53] P. Fuller,et al. Differential gastrin gene expression in rat gastrointestinal tract and pancreas during neonatal development. , 1988, The Journal of biological chemistry.
[54] D. Carter,et al. Pancreatic carcinogenesis-enhancement by cholecystokinin in the hamster-nitrosamine model. , 1985, British Journal of Cancer.
[55] J. Morisset,et al. Cell site and time course of DNA synthesis in pancreas after caerulein and secretin. , 1983, The American journal of physiology.
[56] M. Lampel,et al. Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue , 1977, Virchows Archiv A.
[57] E. Furth,et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. , 2006, Cancer research.
[58] J. P. Smith,et al. Identification of gastrin as a growth peptide in human pancreatic cancer. , 1995, The American journal of physiology.
[59] J. P. Smith,et al. Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines. , 1994, The American journal of physiology.
[60] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[61] J. Holst,et al. Effect of sulfation of CCK-8 on its stimulation of the endocrine and exocrine secretion from the isolated perfused porcine pancreas. , 1981, Digestion.
[62] J. Morisset,et al. Effects of fasting and feeding on protein synthesis by the rat pancreas. , 1972, The Journal of clinical investigation.